Sep 10, 2018

ATXA Therapeutics in Berlin for the EIC Innovators’ Summit 2018

DUBLIN, IRELAND – September 10, 2018 – From 10-11 September 2018, the European Innovation Council (EIC) will host more than 600 top SMEs,...

May 15, 2018

ATXA Therapeutics Secures €2.5m EU Funding for Novel Pulmonary Arterial Hypertension Therapy

DUBLIN, IRELAND – May 15, 2018 – ATXA Therapeutics Limited, an Irish company developing novel therapeutic drugs for the treatment of...

May 10, 2018

Presidential Reception celebrating Female Entrepreneurship, Innovation, Creativity & Sustainable

DUBLIN, IRELAND – May 10, 2018 – Founder & Chief Scientific Officer of ATXA Therapeutics, Prof. Therese Kinsella, attended a reception...

Apr 3, 2018

ATXA Therapeutics to Attend the 2018 Medtech Strategist Innovation Summit

DUBLIN, IRELAND – April 3, 2018 – ATXA Therapeutics Limited Founder and Chief Scientific Officer, Prof. Therese Kinsella, PhD, MRIA, will...

Mar 8, 2018

FDA Grants Orphan Drug Designation to ATXA’s NTP42 for the Treatment of PAH

DUBLIN, IRELAND – March 8, 2018 – ATXA Therapeutics Limited, an early-stage Irish biopharmaceutical company focused on clinical...

Feb 23, 2018

ATXA Therapeutics receives EMA Orphan Drug Designation for NTP42 for the treatment of Pulmonary Arte

DUBLIN, IRELAND – February 23, 2018 – ATXA Therapeutics Limited, an early-stage Irish biopharmaceutical company focused on clinical...

Feb 2, 2018

ATXA Therapeutics to Present at the 2018 Biotech and Money / Medtech and Money World Congress Showca

DUBLIN, IRELAND – February 2, 2018 – ATXA Therapeutics Limited, an early-stage Irish biopharmaceutical company focused on clinical...

COMPANY UPDATES